Company intelligence / Profile preview

北京布霖生物科技

Beijing, Beijing, China

Ownership: Private
Development stage: Other

Overview

Bulin Biotech is a Beijing-based biotechnology company dedicated to the development of next-generation exosome-based therapeutics. The company utilizes its proprietary engineering platform, Bulin-Exo, to create highly specific exosome delivery systems for nucleic acids, proteins, and small molecules. Their primary therapeutic focus includes oncology and inflammatory conditions, where they aim to improve the safety and efficacy of complex payloads. Currently in the pre-clinical stage, Bulin Biotech is actively building a pipeline of candidates designed to address unmet medical needs in hard-to-treat diseases.

Therapeutic areas: OncologyImmunology
Modalities: Exosome-based therapyBiologicRNA therapy
Industry: Biotech

Beyond the preview

Go deeper on 北京布霖生物科技.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 北京布霖生物科技.

Explore the full profile